The role of interleukin-33 in rhinitis

Current Allergy and Asthma Reports

Volumn 13, Issue 2, 2013, Pages 196-202

  Rogala, Barbara ^a   Glück, Joanna ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Allergic inflammation; Basophils; Eosinophils; IL 33 ST2; Interleukin 33; Mast cells; Pathogenesis; Rhinitis; T cells; Th2 mediated response

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; INTERLEUKIN 33; INTERLEUKIN 33 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN RECEPTOR; MESSENGER RNA; UNCLASSIFIED DRUG; IL33 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ALLERGIC RHINITIS; ARTICLE; ASTHMA; BASOPHIL; CYTOKINE RELEASE; CYTOKINE RESPONSE; DRUG MECHANISM; DRUG TARGETING; HUMAN; IMMUNOPATHOGENESIS; MAST CELL; NONHUMAN; PROTEIN EXPRESSION; RESPIRATORY TRACT MUCOSA; RHINITIS; T LYMPHOCYTE; TH2 CELL; EOSINOPHIL; IMMUNOLOGY; PHYSIOLOGY; REVIEW;

BASOPHILS; EOSINOPHILS; HUMANS; INTERLEUKINS; MAST CELLS; RHINITIS; TH2 CELLS;

MLCS; MLOWN;

EID: 84876323440     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-013-0338-z     Document Type: Article

References (65)

1. Miller A. Role of IL-33 in inflammation and disease. J Inflammation. 2011;8:22.
2. • Lloyd CM. IL-33 family members and asthma - bridging innate and adaptive immune responses. Curr Opin Immunol. 2010;22:800-806. A comprehensive review on the role of IL-33 in immune response in asthma.
3. Onda H, Kasuya H, Takakura K, Hori T, Imaizumi T, Takeuchi T, Inoue I, Takeda J. Identification of genes differentially expressed in canine vasospastic cerebral arteries after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 1999;19:1279-88.
4. Baekkevold ES, Roussigné M, Yamanaka T, Johansen FE, Jahnsen FL, Amalric F, Brandtzaeg P, Erard M, Haraldsen G, Girard JP. Molecular characterization of NF-HEV, a nuclaer factor preferentially expressed in human high endothelial venules. Am J Pathol. 2003;163:69-79.
5. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin 1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479-90.
6. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel "alarmin"? PLoS One. 2008;3:e3331.
7. Lamkanfi M, Dixit VM. IL-33 raises alarm. Immunity. 2009;31:5-7.
8. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519-50.
9. Luthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity. 2009;31:84-98.
10. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation of caspase-1. Proc Natl Acad Sci USA. 2009;106:9021-6.
11. Talabot-Ayer D, Lamacchia C, Gabay C, Palmer G. Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem. 2009;284:19420-6.
12. • Ohno T, Morita H, Arae K, Matsumoto K, Nakae S. Interleukin-33 in allergy. Allergy 2012;67:1203-1214. This study presents a comprehensive up-to-date analysis regarding the role of IL-33/ST2 axis in the pathogenesis of allergy.
13. Louten J, Rankin A, Li Y, Murphy E, Beaumont M, Moon C, Bourne P, McClanahan TK, Pflanz S, de Waal Malefyt R. Endogenous IL-33 enhances Th2 cytokine production and T-cell response during allergic airway inflammation. Int Immunol 2011;23307-315
14. Haraldsen G, Balogh J, Pollheimer J, Sponheim J, Kuchler AM. Interleukin-33cytokine of dual function or novel alarmin? Trends Immunol. 2009;30:227-33.
15. Carriere V, Roussel L, Ortega N, Lacorre DA, Amirich L, Aguilar L, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA. 2007;104:282-7.
16. Tago K, Noda T, Hayakawa M, Iwahana H, Yanagisawa K, Yashiro T, Tominaga S. Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2 V. Biochem Biophys Res Commun. 2001;285:1377-83.
17. Hong J, Bae S, Jhun H, Lee S, Choi J, Kang T, Kwak A, Hong K, Kim E, Jo S, Kim S. Identification of constitutively active interleukin 33 (IL-33) splice variant. J Biol Chem. 2011;286:20078-86.
18. Oshikawa K, Yanagisawa K, Tominaga S, Sugiyama Y. Expression and function of the ST2 gene in a murine model of allergic airway inflammation. Clin Exp Allergy. 2002;32:1520-6.
19. Coyle AJ, Lloyd C, Tian J, Nguyen T, Erikkson C, Wang L, Ottoson P, Persson P, Delaney T, Lehar S, et al. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med. 1999;190:895-902.
20. Xu D, Chan WL, Leung BP, Huang FP, Wheeler R, Piedrafita D, Robinson JH, LIew FY. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med. 1998;187:787-94.
21. Lohning M, Stroehmann A, Coyle AJ, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA. 1998;965:6930-5.
22. Chan WL, Pejnovic N, Lee CA, Al-Ali NA. Human IL-18 receptor and ST2L are stable and selective markers for the respective type 1 and type 2 circulating lymphocytes. J Immunol. 2001;167:1238-44.
23. Joshi AD, Oak SR, Hartigan AJ, Finn WG, Kunkel SL, Duffy KE, Das A, Hogaboam CM. Interleukin-33 contributes to both M1 and M2 chemokine marker expression in human macrophages. BMC Immunol. 2010;11:52.
24. Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol. 2008;20:1019-30.
25. Oshikawa K, Kuroiwa K, Tago K, Iwahana H, Yanagisawa K, Ohno S, Tominaga SI, Sigiyama Y. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med. 2001;164:277-81.
26. Ali M, Zhang G, Thomas WR, et al. Investigations into the role of ST2 in acute asthma in children. Tissue Antigens. 2009;73:206-12.
27. Glück J, Rymarczyk B, Rogala B. Serum IL-33 but not ST2 level is elevated in intermittent allergic rhinitis and is a marker of the disease severity. Inflamm Res. 2012;5:547-50.
28. Kamekura R, Kojima T, Takano K, Go M, Sawada N, Himi T. The role of IL-33 and its receptor ST2 in human nasal epithelium with allergic rhinitis. Clin Exp Allergy. 2012;42:218-28.
29. Ali S, Huber M, Kollewe C, BIschoff SC, Falk W, Martin MU. IL-1 receptor accessory protein is Essentials for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci USA. 2007;104:18660-5.
30. Pichery M, Mirey E, Mercier P, Lefrancais E, Dujardin A, Ortega N, Girard JP. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel IL-33-LacZ gene trap reporter strain. J Immunol. 2012;188:3488-95.
31. Zhang L, Lu R, Zhao G, Pflugfelder SC, Li DQ. TLR-mediated induction of pro-allergic cytokine IL-33 in ocular mucosal epithelium. Int J Biochem Cell Biol. 2011;43:1383-91.
32. Wisniewski JA, Borish L. Novel cytokines and cytokine-producing T cells in allergic disorders. Allergy Asthma Proc. 2011;32:83-94.
33. Oliphant C, Barlow JL, McKenzie A. Insights into the initiation of type 2 immune responses. Immunology. 2011;134:378-85.
34. Allakhverdi Z, Smith DE, Comeau M, Delespesse G. Cutting Edge: The ST2 ligand Il-33 potently activates and drives maturation of human mast cells. J Immunol. 2007;179:2051-4.
35. Haenuki Y, Matsushita K, Futatsugi-Yumikura S, Ishii KJ, Tatsukata K, Yoshimasa I, Shigeharu F, Yasuda M, et al. A critical role of IL-33 in experimental allergic rhinitis. J Allergy Clin Immunol. 2012;130:184-94.
36. Iikura M, Suto H, Kajiwara N, Oboki K, Ohno T, Okayama Y, Saito H, Galli SJ, Nakae S. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest. 2007;87:971-8.
37. Kaieda S, Wang JX, Shnayder R, Fishgal N, Nei H, Lee RT, Stevens RL, Nigrovic PA. Interleukin-33 primes mast cells for activation by IgG immune complexes. PLoS One. 2012;7:e47252.
38. Suzukawa M, Likura M, Oketsu R, Nagase H, Tamura C, Komiya A, Nakae S, Matsuhima K, Ohta K, Yamamto K, Yamaguchi M. An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J Immunol. 2008;181:5981-9.
39. Pekaric-Petkovic T, Didichenko SA, Kaempfer S, Spiegl N, Dahinden CA. Human basophils and eosinophils are the direct targer leukocytes of the novel IL-1 family member IL-33. Blood. 2009;113:5981-9.
40. Komai-Koma M, Xu D, Li Y, McKenzie AN, McInnes IB, Liew FY. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol. 2007;37:2779-86.
41. • Kurowska-Stolarska M, Kewin P, Murphy G et al. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol 2008;181:4780-4790. In this study it was show that IL-33 may be involved in IL-4 independent Th2 cell differentiation.
42. Chu DK, Llop-Guevara A, Walker TD, Flader K, Goncharova S, Boudreau JE, Moore CL, Waserman S, Coyle AJ, Kolbeck R, Humbles AA, Jordana M. IL-33, but not thymic stromal lymphopoietin or IL-25, is central to mite and peanut allergic sensitization. J Allergy Clin Immunol. 2013;131:187-200.e8.
43. Kashiwamura S, Kuribayashi K, et al. The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. J Exp Med. 1999;190:1541.
44. Townsend MJ, Fallon PG, Matthews DJ, Jolin HE, McKenzie AN. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med. 2000;191:1069-76.
45. Stolarski B, Kurowska-Stolarska M, Kewin P, Xu D, Liew FY. IL-33 exacerbates eosinophils-mediated airway inflammation. J Immunol. 2010;185:3472-80.
46. Chow JY, Wong CK, Cheung PF, Lam CW. Intracellular signaling mechanisms regulating the activation of human eosinophils by the novel Th2 cytokine IL-33: implications for allergic inflammation. Cell Mol Immunol. 2010;7:26-34.
47. Na HJ, Hudson SA, Bochner BS. IL-33 enhances Siglec-8 mediated apoptosis of human eosinophils. Cytokine. 2012;57:169-74.
48. Cherry WB, Yoon J, Bartemes KR, Lijima K, Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol. 2008;121:1484-90.
49. Kim H, Jun C, Lee Y, et al. Levels of circulating IL-33 and eosinophil cationic protein in patients with hypereosinophilia or pulmonary eosinophilia. J Allergy Clin Immunol. 2010;126:880.
50. Oboki K, Ohno T, Kajiwara N, Saito H, Nakae S. Il-33 and Il-33 receptors in host defense and diseases. Allergol Int. 2010;59:149-60.
51. Sakashita M, Yoshimoto T, Hirota T, Harada M, Okubo K, Osawa Y, et al. Association of serum interleukin-22 level and the interleukin-33 genetic variant with Japanese Cedar pollinosis. Clin Exp Allergy. 2008;38:1875-81.
52. Asaka D, Yoshikawa M, Nakayama T, Yoshimura T, Moriyama H, Otori N. Elevated Levels of Interleukin-33 in the Nasal Secretions of Patients with Allergic Rhinitis. Int Arch Allergy Immunol. 2012;158:47-50.
53. Eiwegger T, Akdis CA. IL-33 links tissue cells, dendritic cells and Th2 cell development in a mouse model of asthma. Eur J Immunol. 2011;41:1535-8.
54. • Kim Y.H, Yang T.Y, Park C.S, Ahn S.H, Son B.K, Kim J.H, Lim D.H, Jang T.Y. Anti-IL-33 antibody has a therapeutic effect in a murine model of allergic rhinitis. Allergy 2012;67:183-190. The results of this experimental study provide an excellent framework for further research aimed at the improvement of allergy inflammation treatment.
55. Kearley J, Buckland KF, Mathic SA, Lloyd CM. Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST1-IL-33 pathway. Am J Respir Crit Care Med. 2009;179:772-81.
56. Liu X, Li M, Wu Y, Zhou Y, Zeng L, Huang T. Anti-IL-33 antibody treatment inhibitis airway inflammation in a murine model of allergic asthma. Biochem Biophys Res Commun. 2009;386:181-5.
57. Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, et al. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med. 2010;363:1211-21.
58. Komai-Koma M, Brombacher F, Pushparaj PN, Arendse B, McSharry C, Alexander J, Chaudhuri R, Thomson NC, McKenzie ANJ, McInnes I, Liew FY, Xu D. Interleukin-33 amplifies IgE synthesis and triggers mast cell degranulation via interleukin-4 in naïve mice. Allergy. 2012;67:1118-26.
59. Ho LH, Ohno T, Oboki K, Kajiwara N, Suto H, Iikura M, et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J Leukoc Biol. 2007;82:1481-90.
60. Kondo Y, Yoshimoto T, Yasuda K, Futatsugi-Yumikura S, Morimoto M, Hayashi N, et al. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol. 2008;20:791-800.
61. Pushparaj PN, Tay HK, H'ng SC, Pitman N, Xu D, McKenzie A, et al. The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci USA. 2009;106:9773-8.
62. Kitamura Y, Mizuguchi H, Ogishi H, Kuroda W, Hatttori M, Fukui H, Takeda N. Preseasonal prophylactic treatment with antihistamines suppresses Il-5 but not Il-33 mRNA expression in the nasal mucosa of patients with seasonal allergic rhinitis caused by Japanese cedar pollen. Acta Oto-Laryngologica. 2012;132:434-8.
63. Préfontaine D, Lajoie-Kadoch S, Foley S, Audusseau S, Olivenstein R, Halayko AJ, Lemière C, Martin JG. Hamid Q1 Increased expression in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol. 2009;15:5094-103.
64. • Reh D, Wang Y, Ramanathan M, Lane AP. Treatment-recalcitrant chronic rhinosinusitis with polyps is associated with altered epithelial cell expression of interleukin-33. Am J Rhinol Allergy 2010;24:105-109. The first study to show evidence that Il-33 is produced by sinonasal epithelial cells derived from chronic sinusitis with nasal polyps, and Il-33 mRNA expression is several higher in patients with recalcitrant disease than those with a responsive disorder.
65. Leung BP, Xu D, Culshaw S, Mcinnes IB, Liew FY. A novel therapy of murine collagen - induced arthritis with soluble T1/ST2. J Immunol. 2004;173:145-50.